CAR-T (Hematologic) Deal Benchmarks in Hematology
Market Analysis
CAR-T (Hematologic) therapies in hematology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 car-t (hematologic) asset in hematology is $751M, with total deal values reaching $3.8B. Development milestones average $639M, while regulatory milestones contribute $761M.
The hematology car-t (hematologic) landscape is characterized by high competitive intensity in lymphoma and myeloma with established treatment paradigms. Bispecific antibodies and next-generation cell therapies are displacing traditional chemotherapy combinations. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.
Royalty rates for car-t (hematologic) hematology deals range from 9.2% to 17.2% at the base tier, with tiered escalation reaching 13.2%-21.2% on blockbuster sales. Commercial milestones averaging $1.6B further reward successful market penetration.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the typical upfront for a car-t (hematologic) hematology licensing deal?
What is the total deal value for car-t (hematologic) hematology transactions?
What royalty rates are standard for car-t (hematologic) deals in hematology?
How are milestones structured in car-t (hematologic) hematology deals?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.